Company / Operating Cash Flow
Boston Scientific Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$4.5B
FY2025
5-year range
$1.5B / $4.5B
FY2021-FY2025
Trend
+32.0%
vs FY2024
Sector context
#11 of 164
Health Care
What the data says
Among 164 Health Care companies, Boston Scientific is in the top 7% for operating cash flow. Operating Cash Flow has increased for 3 consecutive years, from $1.5B in FY2022 to $4.5B in FY2025.
Based on SEC 10-K filings.
$4.5B in FY2025 with a 5-year CAGR of +71.0%. Top quartile in the Health Care sector.
Improved from $2.5B to $4.5B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +43.8%
- 5-Year CAGR
- +71.0%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 164This company $4.5B Sector average $1.0B
▼
+334.4% above sector average
Key checks
Key Insights
- Boston Scientific's operating cash flow has grown for 3 consecutive years.
- 5-year CAGR of +71.0%, indicating consistent growth.
- In FY2025, operating cash flow increased 32.0% year-over-year.
- Ranks #11 out of 164 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.5B | +32.0% |
| FY2024 | $3.4B | +37.2% |
| FY2023 | $2.5B | +64.0% |
| FY2022 | $1.5B | -16.9% |
| FY2021 | $1.8B | +492.3% |
| FY2020 | $310.0M | -83.1% |
| FY2019 | $1.8B | +492.3% |
| FY2018 | $310.0M | -78.3% |
| FY2017 | $1.4B | +20.6% |
| FY2016 | $1.2B | +71.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026